Other: standard immune suppression, oral (DrugBank: -)
1 disease| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 228 | Bronchiolitis obliterans | 1 |
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT01650545 (ClinicalTrials.gov) | July 2012 | 27/6/2012 | Aerosol Liposomal Cyclosporine for Chronic Rejection in Lung Transplant Recipients | A Pilot Study to Demonstrate Efficacy and Safety of Aerosol Liposomal Cyclosporine (L-CsA) in the Treatment of Bronchiolitis Obliterans Syndrome After Lung Transplantation | Disorder Related to Lung Transplantation;Bronchiolitis Obliterans;Decreased Immunologic Activity;Chronic Rejection of Lung Transplant | Drug: Liposomal aerosol cyclosporine;Other: standard immune suppression, oral | University of Maryland, College Park | NULL | Completed | 18 Years | N/A | All | 21 | Phase 1;Phase 2 | United States |